Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Septerna, IPO
Septerna Shares Jump 42% After IPO Shows Biotech Still Hot
Septerna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an enlarged initial public offering.
Septerna Shares Set for Trading Debut After Upsized IPO
Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is selling 16 million shares at $18 apiece in the IPO, up from prior plans to offer about 15.3 million shares.
Septerna proposes terms for upsized $175M IPO
Septerna (SEPN), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial public offering. In its latest SEC filing, Septerna (SEPN) said it was looking to offer 10.
Goldman-backed biotech Septerna targets $628 mln valuation in US IPO
Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.
FierceBiotech
12h
Septerna's $288M IPO is another sign of the market warming to biotech investment
Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...
1d
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO
Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...
BioPharma Dive
22h
GPCR drugmaker Septerna amasses $288M in IPO
Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...
FierceBiotech
4d
Septerna plans $158M IPO to fund clinical readouts for GPCR pipeline
Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...
7h
Septerna Shares Rise 29% on First Trading Day
Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...
ENDPOINTS NEWS
15h
Septerna bags $288M upsized IPO for GPCR drugs
Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...
devdiscourse
5h
Healthcare Headlines: From Weight-Loss Drugs to E. coli Outbreaks
Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...
1d
on MSN
Goldman-backed drug developer Septerna targets $743 million valuation in upsized US IPO
(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Goldman Sachs
Initial public offering
GPCR
Feedback